Evidence map›Paper›PMID 31640958›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2019

[Generation of a novel HBeAg transgenic mice using CRISPR/Cas9 technique].

Rui Guo, Yi Tian, Xueyuan Jin, Haiyan Chen, Guihu Wang, Xiaozhong Huang, Burong Li, Zongfang Li, Jun Yang

Abstract read
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Rui GuoDepartment of Pathology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Yi TianDepartment of Pathology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Xueyuan JinDepartment of Pathology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Haiyan ChenNational & Local Joint Engineering Research Center of Biodiagnostics and Biotherapy, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Guihu WangNational & Local Joint Engineering Research Center of Biodiagnostics and Biotherapy, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Xiaozhong HuangDepartment of Pathology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Burong LiClinical Laboratory, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Zongfang LiNational & Local Joint Engineering Research Center of Biodiagnostics and Biotherapy, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Jun YangDepartment of Pathology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Second Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo generate a new strain of HBeAg transgenic mice using CRISPR/Cas9 technique.

methodsHepatitis B virus (HBV) HBeAg gene was cloned and inserted in the pliver-HBeAg expression frame at the site of Rosa26 gene using CRISPR/Cas9 and homologous recombination techniques to construct the pliver-HBeAg expression vector containing HBeAg gene. The linear DNA fragment containing HBeAg gene was obtained by enzyme digestion. Cas9 mRNA, gRNA and the donor vector were microinjected into fertilized eggs of C57BL/6J mice, which were then transplanted into the uterus of C57BL/6J female surrogate mice to obtain F0 generation mice. The F0 generation mice were identified by long fragment PCR to obtain F0 transgenic mice with HBeAg gene. The positive F0 generation mice were bred with wild-type C57BL/6J mice to produce the F1 mice, which were identified by PCR and sequencing. The positive F1 transgenic mice carrying HBeAg gene were backcrossed until the homozygous offspring transgenic mice were obtained. The genotypes of the offspring mice were identified. The expressions of HBeAg and HBeAb in the heterozygous and homozygous HBeAg transgenic mice were detected by automatic chemiluminescence immunoassay, immune colloidal gold technique and immunohistochemistry method.

resultsA total of 56 F0 mice were obtained, and 2 of them carried homologous recombined HBeAg gene. Six positive F1 mice were obtained, from which 22 homozygous and 29 heterozygous F2 generation HBeAg transgenic mice were obtained. High concentration of HBeAg protein was detected in the peripheral blood of all the positive HBeAg transgenic mice without HBeAb expression. HBeAg expression was detected in the hepatocytes of HBeAg transgenic mice.

conclusionsWe obtained a new strain of HBeAg transgenic mice with stable expression of HBeAg in the hepatocytes and immune tolerance to HBeAg using CRISPR/Cas9 technique, which provide a new animal model for studying HBV.

Indexed as

CRISPR-Cas SystemsMice, TransgenicAnimalsFemaleGenetic VectorsHepatitis B e AntigensHepatitis B virusMiceMice, Inbred C57BLHepatitis B e AntigensC57BL/6J miceCRISPR/Cas9HBeAghepatitis B virustransgenic mice

Identifiers

PMID31640958
PMCPMC6881734
OpenAlexW2984625220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.